J&J: buys investigational dermatological drug
(CercleFinance.com) - Johnson & Johnson's Janssen has completed the acquisition of all the rights for an investigational drug having multiple dermatological indications, the company said on Monday.
The deal, which includes certain employees, has been sealed from XBiotech for 750 million dollars, Janssen said.
Bermekimab is a monoclonal antibody currently in Phase 2 development for the treatment of atopic dermatitis and hidradenitis suppurativa.
Copyright (c) 2019 CercleFinance.com. All rights reserved.
The deal, which includes certain employees, has been sealed from XBiotech for 750 million dollars, Janssen said.
Bermekimab is a monoclonal antibody currently in Phase 2 development for the treatment of atopic dermatitis and hidradenitis suppurativa.
Copyright (c) 2019 CercleFinance.com. All rights reserved.